BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 24792155)

  • 21. Defining early steps in mRNA transport: mutant mRNA in myotonic dystrophy type I is blocked at entry into SC-35 domains.
    Smith KP; Byron M; Johnson C; Xing Y; Lawrence JB
    J Cell Biol; 2007 Sep; 178(6):951-64. PubMed ID: 17846170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular mechanisms in DM1 - a focus on foci.
    Pettersson OJ; Aagaard L; Jensen TG; Damgaard CK
    Nucleic Acids Res; 2015 Feb; 43(4):2433-41. PubMed ID: 25605794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy.
    Wojtkowiak-Szlachcic A; Taylor K; Stepniak-Konieczna E; Sznajder LJ; Mykowska A; Sroka J; Thornton CA; Sobczak K
    Nucleic Acids Res; 2015 Mar; 43(6):3318-31. PubMed ID: 25753670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathogenic mechanisms of myotonic dystrophy.
    Lee JE; Cooper TA
    Biochem Soc Trans; 2009 Dec; 37(Pt 6):1281-6. PubMed ID: 19909263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts.
    Fardaei M; Larkin K; Brook JD; Hamshere MG
    Nucleic Acids Res; 2001 Jul; 29(13):2766-71. PubMed ID: 11433021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myotonic dystrophy associated expanded CUG repeat muscleblind positive ribonuclear foci are not toxic to Drosophila.
    Houseley JM; Wang Z; Brock GJ; Soloway J; Artero R; Perez-Alonso M; O'Dell KM; Monckton DG
    Hum Mol Genet; 2005 Mar; 14(6):873-83. PubMed ID: 15703191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The myotonic dystrophy expanded CUG repeat tract is necessary but not sufficient to disrupt C2C12 myoblast differentiation.
    Amack JD; Mahadevan MS
    Hum Mol Genet; 2001 Sep; 10(18):1879-87. PubMed ID: 11555624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.
    Yadava RS; Yu Q; Mandal M; Rigo F; Bennett CF; Mahadevan MS
    Hum Mol Genet; 2020 Jun; 29(9):1440-1453. PubMed ID: 32242217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic Evaluation of Chimeric LNA/2'-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy.
    Christou M; Wengel J; Sokratous K; Kyriacou K; Nikolaou G; Phylactou LA; Mastroyiannopoulos NP
    Nucleic Acid Ther; 2020 Apr; 30(2):80-93. PubMed ID: 31873063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The CTG repeat expansion size correlates with the splicing defects observed in muscles from myotonic dystrophy type 1 patients.
    Botta A; Rinaldi F; Catalli C; Vergani L; Bonifazi E; Romeo V; Loro E; Viola A; Angelini C; Novelli G
    J Med Genet; 2008 Oct; 45(10):639-46. PubMed ID: 18611984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expanded CTG repeats within the DMPK 3' UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy.
    Orengo JP; Chambon P; Metzger D; Mosier DR; Snipes GJ; Cooper TA
    Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2646-51. PubMed ID: 18272483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FISH Protocol for Myotonic Dystrophy Type 1 Cells.
    Klein AF; Arandel L; Marie J; Furling D
    Methods Mol Biol; 2020; 2056():203-215. PubMed ID: 31586350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defective mRNA in myotonic dystrophy accumulates at the periphery of nuclear splicing speckles.
    Holt I; Mittal S; Furling D; Butler-Browne GS; Brook JD; Morris GE
    Genes Cells; 2007 Sep; 12(9):1035-48. PubMed ID: 17825047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small molecule kinase inhibitors alleviate different molecular features of myotonic dystrophy type 1.
    Wojciechowska M; Taylor K; Sobczak K; Napierala M; Krzyzosiak WJ
    RNA Biol; 2014; 11(6):742-54. PubMed ID: 24824895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Muscleblind-like 1 knockout mice reveal novel splicing defects in the myotonic dystrophy brain.
    Suenaga K; Lee KY; Nakamori M; Tatsumi Y; Takahashi MP; Fujimura H; Jinnai K; Yoshikawa H; Du H; Ares M; Swanson MS; Kimura T
    PLoS One; 2012; 7(3):e33218. PubMed ID: 22427994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction of muscleblind, CUG-BP1 and hnRNP H proteins in DM1-associated aberrant IR splicing.
    Paul S; Dansithong W; Kim D; Rossi J; Webster NJ; Comai L; Reddy S
    EMBO J; 2006 Sep; 25(18):4271-83. PubMed ID: 16946708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy.
    Mahadevan MS; Yadava RS; Yu Q; Balijepalli S; Frenzel-McCardell CD; Bourne TD; Phillips LH
    Nat Genet; 2006 Sep; 38(9):1066-70. PubMed ID: 16878132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of triplet repeat expansion on chromatin structure and expression of DMPK and neighboring genes, SIX5 and DMWD, in myotonic dystrophy.
    Frisch R; Singleton KR; Moses PA; Gonzalez IL; Carango P; Marks HG; Funanage VL
    Mol Genet Metab; 2001; 74(1-2):281-91. PubMed ID: 11592825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sense and Antisense DMPK RNA Foci Accumulate in DM1 Tissues during Development.
    Michel L; Huguet-Lachon A; Gourdon G
    PLoS One; 2015; 10(9):e0137620. PubMed ID: 26339785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DM1 CTG expansions affect insulin receptor isoforms expression in various tissues of transgenic mice.
    Guiraud-Dogan C; Huguet A; Gomes-Pereira M; Brisson E; Bassez G; Junien C; Gourdon G
    Biochim Biophys Acta; 2007 Dec; 1772(11-12):1183-91. PubMed ID: 17950578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.